Title: microRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors
Patent Number: 8,389,210
Filed: Feb. 4, 2010
Lead Inventor: Carlo Croce, Ohio State University
The invention, the patent’s abstract states, “provides novel methods and compositions for the diagnosis, prognosis, and treatment of pancreatic cancer. The invention also provides methods of identifying anti-pancreatic cancer agent.”
Title: Methods and Kits for Synthesis
Patent Number: 8,389,244
Filed: July 31, 2003
Lead Inventor: John Rossi, City of Hope
The patent, its abstract states, claims “amplification-based methods and kits for rapidly producing siRNA expression cassettes. … Also provided are methods for expressing amplified siRNA expression cassettes in cells.”
Title: Encapsulated Nanoparticles for Nucleic Acid Delivery
Patent Number: 8,389,485
Filed: Oct. 29, 2008
Lead Inventor: Michael Czech, University of Massachusetts
The invention, the patent’s abstract states, comprises “methods and compositions for delivering agents and molecules to cells using yeast cell wall particles. ... Embodiments of the invention are particularly useful for the delivery of nucleic acids to cells.”
Title: siRNA-Mediated Gene Silencing of Synuclein
Patent Number: 8,389,487
Filed: Jan. 25, 2010
Lead Inventor: Martha Bohn, Children's Hospital of Chicago
The invention relates to “small interfering RNAs that down-regulate expression of a synuclein gene and methods of using the small interfering RNAs,” the patent’s abstract states.
Title: Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure
Patent Number: 8,389,490
Filed: Sept. 2, 2010
Lead Inventor: Ana Jimenez, Sylentis
The invention, the patent’s abstract states, “relates to methods and compositions that decrease intraocular pressure of the eye. The compositions of the invention comprise short interfering nucleic acid molecules … that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased [intraocular pressure] such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention.”
Title: Method of Cancer Treatment Using siRNA Silencing
Patent Number: 8,389,708
Filed: July 25, 2008
Inventor: Weiping Min, University of Western Ontario
The invention, the patent’s abstract states, relates to a “method for the treatment of cancer involving tumor derived immunosuppression in a subject. The method comprises administering to a subject one or more siRNA constructs capable of inhibiting the expression of an immunosuppressive molecule. The invention also provides siRNA constructs and compositions.”
Title: Compositions and Methods for Treating Tumors, Fibrosis, and Pulmonary Alveolar Proteinosis
Patent Number: 8,389,709
Filed: July 15, 2008
Inventor: Gera Neufeld, Israel Institute of Technology
The patent, its abstract states, claims “pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2.”
Title: Humanized Lewis-Y-Specific Antibody-Based Delivery of Dice-Substrate siRNA against STAT3
Application Number: 20130052731
Filed: March 19, 2012
Lead Inventor: Yuelog Ma, City of Hope
The invention, the patent application’s abstract states, relates to “methods for covalently or non-covalently conjugating an antibody or functional fragment thereof with an siRNA molecule.”
Title: Monomers and Oligonucleotides Comprising Cycloaddition Adducts
Application Number: 20130053334
Filed: Jan. 28, 2011
Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals
The invention, the patent application’s abstract states, relates to “compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.”